Effectiveness of the Japanese COVID-19 vaccine cannot be confirmed in trials
- Why are vegetarians more likely to suffer from depression than meat eaters?
- Small wireless device implanted between skin and skull helps kill cancer cells
- Will the mRNA vaccine that can cure cancer come out near soon?
- Allogeneic T-cell therapy set for landmark first approval
- Boston University denies that the new COVID strain they made has 80% fatality rate
- A new generation of virus-free CAR-T cell therapy
Effectiveness of the Japanese COVID-19 vaccine cannot be confirmed in trials
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Where do the bacteria in the human gut come from?
Japan gets a bad news: Effectiveness of the Japanese COVID-19 vaccine cannot be confirmed in trials.
According to a report from Kyodo News on the 28th, AnGes, a Japanese pharmaceutical company from Osaka University, admitted that a COVID-19 vaccine it developed could not confirm its effectiveness in clinical trials.
Earlier this month, AnGes announced the results of vaccine clinical trials conducted on 560 people on its company homepage, stating that “the expected results have not been obtained” and “it is necessary to improve the effectiveness”.
According to Kyodo News, due to the inability to confirm the effectiveness in clinical trials, the launch of AnGes’ COVID-19 vaccine has also been postponed from 2021 to 2023.
Earlier, Japanese media pointed out that as early as March 2020, AnGes announced the start of the development of a COVID-19 vaccine, becoming the first company in Japan to start a COVID-19 vaccine clinical trial, and was once praised by Japanese media as a “Japanese vaccine pioneer.”
The founder of AnGes previously said in an interview with Taiwanese media: “I saw AstraZeneca’s supply contract with Japan and knew that the other party had the final say… Countries that cannot produce vaccines on their own are very miserable.”
Kyodo News said that the Japanese can now only hope that companies such as Shiono Yoshitaka, which were originally “half a beat”, will be the first to launch Japanese-made vaccines.
(source:internet, reference only)
Disclaimer of medicaltrend.org
